Technical Analysis for AMAG - AMAG Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 8.65 -3.89% -0.35
AMAG closed down 3.89 percent on Wednesday, July 17, 2019, on approximately normal volume.

Earnings due: Aug 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical AMAG trend table...

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -3.89%
NR7 Range Contraction -3.89%
NR7-2 Range Contraction -3.89%
NR7 Range Contraction -6.28%
Hammer Candlestick Bullish -6.69%
Fell Below 20 DMA Bearish -6.28%
Down 3 Days in a Row Weakness -6.28%
Down 4 Days in a Row Weakness -6.28%
Down 5 Days in a Row Weakness -6.28%

Older signals for AMAG ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The company's principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company also markets Feraheme in Canada, the European Union, and Switzerland. In addition, its development projects comprise Feraheme for patients with IDA regardless of the underlying cause, which has completed Phase III clinical program. The company sells Feraheme primarily to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as a therapeutic agent in China for an initial indication for the treatment of IDA in patients with CKD and an option to expand into additional therapeutic indications. The company was founded in 1981 and is headquartered in Lexington, Massachusetts.
Health Biopharmaceutical Medication Chronic Kidney Disease European Union
Is AMAG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.1
52 Week Low 7.81
Average Volume 922,717
200-Day Moving Average 14.6173
50-Day Moving Average 9.7922
20-Day Moving Average 9.376
10-Day Moving Average 9.459
Average True Range 0.4642
ADX 21.53
+DI 17.0668
-DI 28.7365
Chandelier Exit (Long, 3 ATRs ) 9.0774
Chandelier Exit (Short, 3 ATRs ) 9.2026
Upper Bollinger Band 10.4622
Lower Bollinger Band 8.2898
Percent B (%b) 0.17
BandWidth 23.169795
MACD Line -0.1864
MACD Signal Line -0.1251
MACD Histogram -0.0613
Fundamentals Value
Market Cap 305.24 Million
Num Shares 35.3 Million
EPS -1.30
Price-to-Earnings (P/E) Ratio -6.65
Price-to-Sales 0.90
Price-to-Book 0.57
PEG Ratio 0.30
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.34
Resistance 3 (R3) 9.41 9.24 9.23
Resistance 2 (R2) 9.24 9.07 9.21 9.19
Resistance 1 (R1) 8.95 8.96 8.87 8.88 9.15
Pivot Point 8.78 8.78 8.74 8.75 8.78
Support 1 (S1) 8.49 8.61 8.41 8.42 8.15
Support 2 (S2) 8.32 8.50 8.29 8.11
Support 3 (S3) 8.03 8.32 8.08
Support 4 (S4) 7.96